The TAILORx trial: Individualized options for treatment

Because predicting treatment benefit is imprecise, when faced with making a decision on whether to accept adjuvant chemotherapy, many patients with ER-positive breast cancer and their clinicians err on the side of overtreatment. The TAILORx trial will attempt to reduce overtreatment by integrating a molecular diagnostic test into clinical decision making; identifying the utility of chemotherapy in patients where the molecular test gives a result of uncertain clinical significance; and serving as a resource to evaluate new molecular tests as they develop. This article describes the trial and how clinicians can enroll their patients.